Applying bioethical principles for directing investment in precision medicine

The concept of precision medicine aims to tailor treatment based on data unique to the patient. An example is the use of genetic data from malignant tumours to select the most appropriate oncological treatment. The competing interests of utilitarianism and egoism create dilemmas for decisions regarding investment in precision medicine. The need to balance the perceived rights and needs of individuals against those of society as a whole is an on-going challenge in the distribution of limited health service resources. There is need for proper planning, organisation and investment into precision medicine to cope with the consequences of both direct-to-consumer and healthcare-directed genetic testing for genetic counselling, therapeutics and diagnostic networks. Consideration needs to be given to providing adequate time and training to allow for meaningful shared decision-making with patients and there is a strong case in support of a hub-and-spoke model to provide rapid, solid tumour genetic mutational analysis to prevent patients missing out on beneficial treatments.

[1]  N. Ikeda,et al.  Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Wjst,et al.  The challenges of the expanded availability of genomic information: an agenda-setting paper , 2017, Journal of Community Genetics.

[3]  D. Meaney-Delman,et al.  Direct-to-Consumer Personal Genome Testing and Cancer Risk Prediction , 2012, Cancer journal.

[4]  Gail Javitt,et al.  The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues. , 2008, Annual review of genomics and human genetics.

[5]  Cath Taylor,et al.  Multidisciplinary team working in cancer: what is the evidence? , 2010, BMJ : British Medical Journal.

[6]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Adam Smith,et al.  The Wealth of Nations , 1999 .

[8]  C. Eng,et al.  Breast cancer risk and clinical implications for germline PTEN mutation carriers , 2017, Breast Cancer Research and Treatment.

[9]  Angela Brand,et al.  European healthcare systems readiness to shift from 'one-size fits all' to personalized medicine. , 2017, Personalized medicine.

[10]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[11]  R. McCormack,et al.  EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). , 2015, American journal of cancer research.

[12]  Gary W Procop,et al.  Prospective Clinical Study of Precision Oncology in Solid Tumors. , 2015, Journal of the National Cancer Institute.

[13]  S. Athar.  Principles of Biomedical Ethics , 2011, The Journal of IMA.

[14]  J. Dixon,et al.  Productivity in the NHS: why it matters and what to do next , 2018, British Medical Journal.

[15]  R. Gillon.  Where respect for autonomy is not the answer. , 1986, British medical journal.

[16]  A. Stiggelbout,et al.  Shared Decision Making and the Importance of Time. , 2019, JAMA.

[17]  J Dixon.  Performance and productivity , 2000, BMJ : British Medical Journal.

[18]  Sarah Thornton.  Time to review utility of multidisciplinary team meetings , 2015, BMJ : British Medical Journal.

[19]  J. Benneyan,et al.  Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review. , 2017, Lung cancer.

[20]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[21]  J. Garber,et al.  Guidelines for Genetic Risk Assessment of Hereditary Breast and Ovarian Cancer: Early Disagreements and Low Utilization , 2009, Journal of General Internal Medicine.

[22]  M. Beach,et al.  Realizing Shared Decision-making in Practice. , 2019, JAMA.

[23]  Levi A Garraway,et al.  Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Ruth Chadwick,et al.  The Right to Know and the Right Not to Know: Genetic Privacy And Responsibility , 2014 .

[25]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[26]  T. Hope,et al.  Medical Ethics: A Very Short Introduction , 2004, Very Short Introductions.

[27]  Laurie Udesky,et al.  The ethics of direct-to-consumer genetic testing , 2010, The Lancet.

[28]  Ian Matthews,et al.  Epidemiology and Public Health Medicine , 1999 .

[29]  I. Heath.  Back to the future: aspects of the NHS that should never change—an essay by Iona Heath , 2018, British Medical Journal.

[30]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[31]  C. Eng,et al.  Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet , 2016, npj Genomic Medicine.

[32]  Heather Skirton,et al.  Direct-to-consumer genomic testing: systematic review of the literature on user perspectives , 2012, European Journal of Human Genetics.

[33]  G. Elwyn,et al.  Knowledge is not power for patients: a systematic review and thematic synthesis of patient-reported barriers and facilitators to shared decision making. , 2014, Patient education and counseling.

[34]  Ann Barrett,et al.  How much will Herceptin really cost? , 2006, BMJ : British Medical Journal.

[35]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[36]  M. Parker.  Ethical Problems and Genetics Practice , 2012 .

[37]  G. Giaccone.  The Role of Gefitinib in Lung Cancer Treatment , 2004, Clinical Cancer Research.

[38]  A. McGuire,et al.  Regulating Direct-to-Consumer Personal Genome Testing , 2010, Science.

[39]  R. Green,et al.  Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Glyn Elwyn,et al.  Assessments of the extent to which health‐care providers involve patients in decision making: a systematic review of studies using the OPTION instrument , 2015, Health expectations : an international journal of public participation in health care and health policy.

[41]  A. Oton,et al.  Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer. , 2017, Journal of managed care & specialty pharmacy.

[42]  R. Green,et al.  The impact of direct-to-consumer personal genomic testing on perceived risk of breast, prostate, colorectal, and lung cancer: findings from the PGen study , 2015, BMC Medical Genomics.

[43]  Kenneth E. Rosenzweig,et al.  Scientific Advances in Lung Cancer 2015 , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[44]  J. Klein,et al.  Using industrial processes to improve patient care , 2004, BMJ : British Medical Journal.

[45]  D. Aisner,et al.  Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[46]  Amy L. McGuire,et al.  An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. , 2008, JAMA.

[47]  Y. Wu,et al.  Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.